Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Over 11 million Americans have both diabetes and hypertension-comorbid diseases that strongly predispose people to both renal as well as cardiovascular (CV) injury. Hypertension substantially contributes to CV morbidity and mortality in people with diabetes. Diabetes is the most common cause of end-stage renal disease in the United States. Furthermore, hypertension and diabetes are particularly prevalent in certain populations, such as African-Americans and Native Americans. Since the 1994 Working Group Report on Hypertension and Diabetes, a large body of clinical trial data has affirmed the original blood pressure goal of less than 130/85 mmHg recommended to preserve renal function and reduce CV events in people with hypertension and diabetes. Data that are more recent have emerged, however, to support an even lower diastolic blood pressure goal, ie, 80 mmHg, in order to optimally preserve renal function and reduce CV events in people with diabetic nephropathy. A review of clinical trials indicates that more than 65% of people with diabetes and hypertension will require two or more different antihypertensive medications to achieve the new suggested target blood pressure of 130/80 mmHg. The purpose of this report is to update the previous recommendations with a focus on level of blood pressure control, proteinuria reduction, and therapeutic approaches to achieve these goals. We provide an evidence-based approach, integrating data from the major clinical trials that were designed as randomized prospective, long-term studies that had as a primary endpoint either progression of diabetic nephropathy or reduction in CV events. This report also addresses socioeconomic and cultural barriers that hinder achievement of blood pressure goals. Lastly, the report discusses approaches to resolve cultural barriers, both physician- and patient-derived, that interfere with achievement of lower blood pressure goals.

[1]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[2]  B. Iversen,et al.  Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR. , 1998, American journal of physiology. Renal physiology.

[3]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[4]  J. Miller,et al.  Early predictors of 15-year end-stage renal disease in hypertensive patients. , 1995, Hypertension.

[5]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[6]  G. Bakris,et al.  Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. , 1996, Archives of internal medicine.

[7]  M. Ravid,et al.  Risk factors for nephropathy in type 2 diabetes mellitus , 1999, Comprehensive therapy.

[8]  G. Bakris,et al.  Preservation of renal function: the spectrum of effects by calcium-channel blockers. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[10]  M. Ravid,et al.  Effect of an α-Adrenergic Blocker, and ACE Inhibitor and Hydrochlorothiazide on Blood Pressure and on Renal Function in Type 2 Diabetic Patients with Hypertension and Albuminuria , 1998, Nephron.

[11]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[12]  G. Bakris,et al.  Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. , 1998, Kidney international.

[13]  E. Ritz,et al.  Renal disease and hypertension in non-insulin-dependent diabetes mellitus. , 1999, Kidney international.

[14]  L. Prisant,et al.  Verapamil and Nifedipine in Combination for the Treatment of Hypertension , 1994, Journal of clinical pharmacology.

[15]  G. Wolf,et al.  Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension. , 1989, Journal of hypertension.

[16]  The Gisen Group Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy , 1997, The Lancet.

[17]  O. Ifudu Benefits of Combination Antihypertensive Therapy in Progressive Chronic Renal Failure , 1999 .

[18]  G. Eknoyan,et al.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  C. Lewis,et al.  Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS) , 1997, Hypertension.

[20]  M. Lishner,et al.  Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. , 1996, Archives of internal medicine.

[21]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[22]  Detection The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[23]  H. Black,et al.  Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2000, Archives of internal medicine.

[24]  P. Fioretto,et al.  Effects of Cilazapril and Amlodipine on Kidney Function in Hypertensive NIDDM Patients , 1996, Diabetes.

[25]  C. Mogensen,et al.  Renal Factors Influencing Blood Pressure Threshold and Choice of Treatment for Hypertension in IDDM , 1991, Diabetes Care.

[26]  L. Prisant,et al.  Sexual dysfunction with antihypertensive drugs. , 1994, Archives of internal medicine.

[27]  P. Whelton,et al.  End-stage renal disease in African-American and white men. 16-year MRFIT findings. , 1997, JAMA.

[28]  R. Holman,et al.  Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. , 1999, Archives of internal medicine.

[29]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[30]  Philip D. Harvey,et al.  Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.

[31]  G. Bakris,et al.  ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. , 1994, Journal of diabetes and its complications.

[32]  G. Bakris,et al.  Effects of Sodium Intake on Albumin Excretion in Patients with Diabetic Nephropathy Treated with Long-Acting Calcium Antagonists , 1996, Annals of Internal Medicine.

[33]  F. Locatelli,et al.  The renoprotective effect of antihypertensive drugs. , 1998, Journal of nephrology.

[34]  A. Stewart,et al.  Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. , 1997, Archives of internal medicine.

[35]  Bruce Neal,et al.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. , 1999, Journal of hypertension.

[36]  R B Haynes,et al.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[37]  R. Toto,et al.  Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. , 1996, Controlled clinical trials.

[38]  W. Elliott,et al.  Circadian variation in the timing of stroke onset: a meta-analysis. , 1998, Stroke.

[39]  J. Coope,et al.  The prognostic significance of blood pressure in the elderly. , 1988, Journal of human hypertension.

[40]  S. Willich,et al.  Circadian variation and triggering of cardiovascular events , 1999, Vascular medicine.

[41]  O. Pedersen,et al.  White Coat Hypertension in NIDDM Patients With and Without Incipient and Overt Diabetic Nephropathy , 1997, Diabetes Care.

[42]  B. Davis,et al.  The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. , 2001, Controlled clinical trials.

[43]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[44]  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[45]  N. Kaplan J-curve not burned off by HOT study , 1998, The Lancet.

[46]  R. Toto,et al.  Hypertension in patients with diabetes , 2000, Postgraduate medicine.

[47]  Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996 .

[48]  G. Remuzzi,et al.  Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). , 1998, Journal of the American Society of Nephrology : JASN.

[49]  H. Parving,et al.  Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. , 1997, Kidney international.

[50]  I. Wiklund,et al.  Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. , 1997, Blood pressure.

[51]  J. Birkmeyer,et al.  The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors , 1999, Annals of Internal Medicine.

[52]  R. Bain,et al.  Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[53]  P Whelton,et al.  Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. , 1995, Hypertension.

[54]  R. Rodby,et al.  An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy , 1996, Diabetes Care.

[55]  B. Morgenstern,et al.  Human blood pressure determination by sphygmomanometry. , 1993, Circulation.

[56]  M. Schroll,et al.  Urinary albumin excretion. An independent predictor of ischemic heart disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[57]  R. Marfella,et al.  Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and Hypertension , 1997, Annals of Internal Medicine.

[58]  F. Gudé,et al.  Atherosclerosis profile and microalbuminuria in essential hypertension. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[59]  E. Ritz,et al.  Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.

[60]  S. Greenhouse,et al.  Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. , 1994, Kidney international.

[61]  G. Bakris,et al.  Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. , 1997, Hypertension.

[62]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[63]  C. Tzourio,et al.  Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke. , 1997, Circulation.

[64]  Nie Fe Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II) , 1990 .

[65]  S. Anderson Renal Hemodynamic Effects of Calcium Antagonists in Rats With Reduced Renal Mass , 1991, Hypertension.

[66]  R B D'Agostino,et al.  Influence of heart rate on mortality among persons with hypertension: the Framingham Study. , 1993, American heart journal.

[67]  B Neal,et al.  1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. , 1999, Clinical and experimental hypertension.

[68]  G. Bakris,et al.  Class differences in the effects of calcium channel blockers in the rat remnant kidney model. , 1999, Kidney international.

[69]  C. Grim,et al.  A curriculum for the training and certification of blood pressure measurement for health care providers. , 1995, The Canadian journal of cardiology.

[70]  K. Tuttle,et al.  Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[71]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[72]  A. Ojo,et al.  Aggressive blood pressure control may eliminate racial disparity in hypertensive renal disease: the hypertension optimal treatment trial (hot study) , 1999 .

[73]  G. Bakris,et al.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? , 2000, Archives of internal medicine.

[74]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[75]  K. Resch,et al.  Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. , 1994, Kidney international.

[76]  D. Hilleman Cost Effectiveness of Combination Therapy , 1999 .

[77]  H. Lebovitz,et al.  Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. , 1994, Kidney international. Supplement.

[78]  M. Pfeffer,et al.  Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[79]  W. Kannel,et al.  Risk stratification in hypertension: new insights from the Framingham Study. , 2000, American journal of hypertension.

[80]  A. Levey,et al.  Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. , 1997, Hypertension.

[81]  R. Schrier,et al.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.

[82]  G. Bakris,et al.  Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. , 1994, Kidney international.

[83]  H. Black,et al.  Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. , 1996, Hypertension.

[84]  G. Bakris,et al.  Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. , 1999, American journal of hypertension.

[85]  G. Bakris,et al.  Therapeutic challenges in the obese diabetic patient with hypertension. , 1996, The American journal of medicine.

[86]  B. Davis,et al.  Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.

[87]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[88]  D. Levy,et al.  Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. , 1994, Circulation.

[89]  S. Leurgans,et al.  Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. , 1996, Kidney international.

[90]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[91]  E. B. Tylor Primitive Culture: Researches Into the Development of Mythology, Philosophy, Religion, Art, and Custom , 1974 .

[92]  P. Whelton,et al.  Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.

[93]  M. Safar,et al.  The Diastolic Blood Pressure in Systolic Hypertension , 2000, Annals of Internal Medicine.

[94]  G. Bakris Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals. , 1999, Journal of clinical hypertension.

[95]  M. Matsuda,et al.  Effects of Angiotensin-Converting Enzyme Inhibitors, Ca2+ Channel Antagonists, and α-Adrenergic Blockers on Glucose and Lipid Metabolism in NIDDM Patients With Hypertension , 1995, Diabetes.